Stopping a trial early in oncology: For patients or for industry?

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1347-1353

  Trotta, F ^a   Apolone, G ^b   Garattini, S ^b   Tafuri, G ^a,c  

^a ITALIAN MEDICINES AGENCY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer drugs; EMEA; End point; FDA; Interim analysis; RCT

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IDOXIFENE; IODINATED POPPYSEED OIL; IRINOTECAN; LAPATINIB; LETROZOLE; MELPHALAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; UFT; UNINDEXED DRUG; VINBLASTINE;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED MEDICINE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL; TIME MANAGEMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG INDUSTRY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 44949205473     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn042     Document Type: Article

References (35)

1. The European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95/Rev.3/Corr.2). London: European Medicines Agency 2005.
2. Bertele' V, Banzi R, Capasso F et al. Haematological anticancer drugs in Europe: Any added value at the time of approval? Eur J Clin Pharmacol 2007; 63: 713-719.
3. Apolone G, Joppi R, Bertele' V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 2005; 93: 504-509.
4. Johnson JR, Williams, G, Pazdur R. End points and United States Food and Drug Administration approval 6f oncology drugs. J Clin Oncol 2003; 21: 1404-1411.
5. van Luijn JC, Gribnau FW, Leufkens HG. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization, Br J Clin-Pharmacol 2007; 63: 159-162.
6. Montori VM, Devereaux PJ, Adhikari NK et al. Randomized trials stopped early for benefit: A systematic review. JAMA 2005; 294: 2203-2209.
7. Facon T, Mary JY, Hulin C et al. Intergroupe Francophone du Myelome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007; 370: 1209-1218.
8. Hudes G, Carducci M, Tomczak P et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
9. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
10. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
11. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
12. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
13. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal turnout after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-1338.
14. Goldberg RM, Sargent DJ, Morton RF et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006; 24: 3347-3353.
15. Akasu T, Moriya Y, Ohashi Y et al. National Surgical Adjuvant Study of Colorectal Cancer. Adjuvant chemotherapy with uracil-tegatur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: A multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36: 237-244.
16. Reed NS, Poole CJ, Coleman R et al. Scottish Gynaecological Cancer Trials Group (SGCTG). A randomised comparison of treosulfain and carboplatin in patents with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer 2006; 42: 179-185.
17. Lehmann J, Franzaring L, Thuroff J et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer, BJU Int 2006; 97: 42-47.
18. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant (HERA) Trial Study, Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med 2005; 353: 1659-1672.
20. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
21. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamofoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
22. Moore Mj, Hamm J, Dancey J et al. National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase. inhibitor BAY12-9566 in patents with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-3302.
23. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
24. Arpino G, Nair KM, Doval DC et al. Idoxifene versus tamoxifen: A randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol 2003; 14: 233-241.
25. Radford A Rohatiner AZ, Ryder WD et al. ChIVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988-2994.
26. Noda K, Nishiwaki-Y, Kawahara M et al. Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
27. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-4244.
28. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001; 34 (Suppl 4): S65-S69.
29. Cornelia P, Frasci G, Panza N et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000; 18: 1451-1457.
30. Lau WY, Leung TW, Ho SK et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: A prospective randomised trial. Lancet 1999; 353: 797-801.
31. Kurth K, Tunn U, Ay R et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997; 158: 378-384.
32. Pocock SJ. Wh6n (not) to stop a clinical trial for benefit. JAMA 2005; 294: 2228-2230.
33. Schulz KF, Grimes DA. Multiplicity in randomised trials II: Subgroup and interim analyses. Lancet 2005; 365: 1657-1661.
34. Grant A. Stopping clinical trials early. BMJ 2004; 329: 525-526.
35. Doll R, The role of data monitoring committees. In Duley L, Farrell B (eds): Clinical Trials. London: BMJ Publishing Group 2001; 97-104.